Genmab — Marts 2017
-
Endvidere "We see upside to the guidance based on:
• Daily sales projections using the growth trend for the past 12 months (6-7%), suggesting USD 1.1bn in US Darzalex sales in 2017 (see calculations below), with the European sales then being added.
• Potential label expansion in third-line to include a Pomalyst combination.
• Potential off-label sales in frontline MM driven by the upcoming frontline data likely for release in H2." -
Rachel opsummerede i går på Investordagen, at der er ialt 40 igangværende forsøg med Dara
. -
Mekanismen bag Daras virkning på immunforsvaret er videnskabeligt klarlagt, men endnu ikke bevist i klinikken.
-
I return to this later. Eventually remind me, please. I´m on my way to a meeting.
-
og nu skriver Børsen, at februar salget er 0.1% under salget i Januar!! Og det giver man 4500kr per år for!
-
kl 0908
-
-
det giver 61.5 for jan og 62.1 i feb
-
er det et fald på 0.1%
-
Jeg tror ikke det fald vi ser nu har noget som helst med salgstallet at gøre. Det er den generelle usikkerhed om trumpetens behandling af pharma der er på dagsorden igen sammen med at der breder sig en følelse af, at trumpetens lovede tiltag for erhverslivet måske er lige så vidtløftige som andre udmeldinger.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind